Status:
COMPLETED
Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Lead Sponsor:
Boston Children's Hospital
Conditions:
Adrenal Hyperplasia, Congenital
Eligibility:
All Genders
2-9 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocort...
Detailed Description
This is a Phase II clinical trial, intended to estimate the effect of instituting Dexamethasone therapy in comparison to prior standard therapy. Each subject provides his own baseline data. There is n...
Eligibility Criteria
Inclusion
- Classic salt-wasting 21-hydroxylase deficient congenital adrenal hyperplasia
- Pre-pubertal children with bone ages below 8 years
Exclusion
- Age less than 2 years
- Patients with additional medical conditions necessitating glucocorticoid therapy.
- Patients on phenytoin, barbiturates, and rifampin as these medications accelerate the metabolism of glucocorticoids.
- Patients on ketoconazole as this medication increases the bioavailability of glucocorticoids.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00621985
Start Date
April 1 2008
End Date
June 1 2009
Last Update
February 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Boston
Boston, Massachusetts, United States, 02115